...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers.
【24h】

Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers.

机译:普通恩丹西酮制剂在健康的泰国男性志愿者中的药代动力学和生物等效性测试。

获取原文
获取原文并翻译 | 示例

摘要

SUBJECTS, MATERIAL AND METHODS: Pharmacokinetics and bioequivalence of oral preparations of generic ondansetron were investigated in healthy Thai males. The test preparations were Vomitron 8 and Vomitron 4, the reference was Zofran. The three products were administered as an 8 mg single oral dose, in a three-period four-sequence cross-over design with one-week washout period. An intravenous 8 mg Zofran was administered on the forth visit. Plasma ondansetron concentrations were determined by HPLC and the pharmacokinetic parameters were analyzed by non-compartmental analysis. RESULTS: Following i.v. ondansetron, the mean values of its elimination half-life, its plasma clearance, and its volume of distribution were 4.5 hours, 398 ml/min, and 130 liters, respectively. Its oral bioavailability averaged 67%, and the elimination half-life after oral administration was 5.6 hours. The time to reach the maximal concentration (Tmax, hour) of Zofran (1.21 +/- 0.26) was statistically faster than that of Vomitron 8 (1.33 +/- 0.54) and Vomitron 4 (1.46 +/- 0.50). The 90% confidence intervals of the AUC0-infinity and Cmax ratios muT/muR for (Vomitron 8/Zofran) were 0.88 - 1.12 and 0. 85 - 1.08, respectively. Similarly the 90% CI of the-AUC0-infinity and Cmax ratios for (Vomitron 4/Zofran) were 0.96 - 1.17 and 1.01 - 1.19, respectively. CONCLUSION: These values were within the acceptable range of 0.80 - 1.25, thus our study demonstrated the bioequivalence of Vomitron and Zofran with respect to the rate (Cmax) and extent of absorption (AUC0-infinity).
机译:受试者,材料和方法:在泰国健康男性中研究了通用恩丹西酮口服制剂的药代动力学和生物等效性。测试准备为Vomitron 8和Vomitron 4,参考文献为Zofran。三种产品以8毫克单次口服剂量的形式进行,采用三周期四序列交叉设计,冲洗期为一周。第四次就诊时静脉注射8 mg Zofran。通过HPLC测定血浆昂丹司琼浓度,并通过非房室分析法分析药代动力学参数。结果:i.v.之后恩丹西酮的消除半衰期,血浆清除率和分布体积的平均值分别为4.5小时,398毫升/分钟和130升。其口服生物利用度平均为67%,口服后消除半衰期为5.6小时。在统计上,达到Zofran(1.21 +/- 0.26)的最大浓度(Tmax,小时)的时间比Vomitron 8(1.33 +/- 0.54)和Vomitron 4(1.46 +/- 0.50)快。 (Vomitron 8 / Zofran)的AUC0-无穷大和Cmax比muT / muR的90%置信区间分别为0.88-1.12和0. 85-1.08。类似地,(Vomitron 4 / Zofran)的-AUC0-无穷大和Cmax比率的90%CI分别为0.96-1.17和1.01-1.19。结论:这些值在0.80-1.25的可接受范围内,因此我们的研究证明了Vomitron和Zofran在吸收速率(Cmax)和吸收程度(AUC0-无穷大)方面具有生物等效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号